The Presence of Anti-Phosphatidylethanolamine Antibodies in Acute Myocardial Infarction

Abstract

Acute Myocardial Infarction (AMI) is a clinical manifestation of coronary atherothrombosis and is the important causes of death. Many factors play a role in AMI. Anti-Phospholipid (aPL) antibodies may act in the induction of immunological response leading to the development of AMI. AntiPhosphatidylethanolamine (aPEA) antibody has been detected in various autoimmune diseases and anti-phospholipid antibody syndrome. The study of aPEA antibody in AMI might shed light on etiologic mechanisms in the pathogenesis of coronary atherothrombosis and AMI. This study was aimed to evaluate whether prevalence of aPEA antibodies, in patients with AMI and to analyze their relationship with traditional cardiovascular risk factors. The prevalence of aPEA IgG and IgM in a well characterized group of patients with AMI as a case group and in age and sex matched healthy subjects as a control group. Sera from two groups were tested to evaluate the presence of aPEA IgG and IgM isotypes by ELISA method. The frequencies of positive test for aPEA IgG were 12.22 and 2.22% among patients and controls respectively with significant difference (p = 0.007). The aPEA IgM frequencies were 3.33 and 0.00% in patients and the controls, with significant difference (p = 0.005). According to the results of this study, aPEA antibodies have a role in AMI, independent risk factors for AMI, which may represent a link between autoimmunity and coronary atherothrombosis. Further studies with larger sample size of patients and healthy people are needed to explore the role of aPEA antibodies in coronary atherothrombosis.

A Comparative Study of Anti-Phosphatidyl Inositole Antibodies in Patients With Myocardial Infarction and Healthy Subjects

“…The same results were found about anti-PL IgG in AMI in other studies (Yamada et al, 2010;Jahromi et al, 2013b;2013c).…”

“…There was not found correlation between anti-PI Abs (IgG, IgM) and standard cardiovascular risk factors such as smoking, hypertension and diabetes which is agreement with previous studies (Shojaie and Jahromi, 2011;Jahromi et al, 2010a;2010b;2013b;2013c).…”

“…As there were not significant differences between positive anti-PI Abs test in patients with STEMI and those with NSTEMI, it can be concluded that anti-PI IgG and IgM do not participate in kind of AMI (STEMI Vs NSTEMI), which is parallel with our previous studies (Jahromi et al, 2013b;2013c).…”

“…Other aPLs have been reported to have association with CAD and AMI (Shojaie and Jahromi, 2011;Jafarzadeh et al, 2011;Greco et al, 2010;Urbanus et al, 2009;Jahromi et al, 2013b;2013c).…”

“…The results of some studies also demonstrated an association between anti-PL Ab and Ischemic Heart Disease (IHD) (Shojaie and Jahromi, 2011;Jafarzadeh et al, 2001;Jahromi et al, 2013b;2013c). It should be noted that genetic factors as well as other traditional risk factors such as smoking, hypercholesterolemia, diabetes mellitus and hypertension may contribute to IHD development and these parameters differ among various population.…”